# DESCRIPTION

## FIELD OF THE INVENTION

- relate to characterizing PEGylated htCBS conjugates

## BACKGROUND OF THE INVENTION

- introduce human cystathionine beta-synthase
- describe CBS function and regulation
- explain classical homocystinuria and its symptoms
- discuss current treatment of HCU
- introduce enzyme replacement therapy using PEGylated htCBS
- highlight need for reproducible and controlled PEGylated htCBS conjugates

## SUMMARY OF THE INVENTION

- introduce method of PEGylating htCBS C15S
- describe conjugation of htCBS C15S with NHS ester PEG molecules
- identify insufficient PEGylation using SEC-HPLC or NR-CE analysis
- add additional NHS ester PEG molecules to reduce insufficient PEGylation
- provide methods for maintaining efficacy of treatment for homocystinuria
- provide pharmaceutical composition including PEGylated htCBS C15S

## DETAILED DESCRIPTION OF THE INVENTION

### I. Introduction

- introduce homocystinuria and need for enzyme replacement therapy
- describe development of PEGylated human truncated CBS (PEG-htCBS)
- motivate PEGylation of htCBS C15S
- summarize limitations of current treatments for homocystinuria
- describe goal of reducing plasma homocysteine levels
- introduce PEGylation of therapeutic macromolecules
- describe PEGylation of phenylalanine ammonia-lyase (PAL)
- discuss homocysteine metabolism and pathophysiology

### II. Methods of Characterizing Pegylated HtCBS C15S

- describe extent of PEGylation of htCBS C15S
- summarize size exclusion chromatography (SEC)-high performance liquid chromatography (HPLC) analysis
- describe non-capillary electrophoresis and liquid chromatography-mass spectrometry (LC-MS) analysis
- discuss optimizing PEG conjugation
- describe removal of residual ammonium sulfate and unreacted PEG molecules

### III. Treatment with PEGylated HtCBS C15S

- describe administration of PEGylated htCBS C15S to reduce homocysteine levels
- summarize therapeutic effects of PEGylated htCBS C15S administration

### IV. Dosing and Administration

- outline administration methods
- specify dosing frequencies
- describe dosing schedules
- outline administration with betaine
- specify dosing amounts
- describe co-administration with other therapeutics
- define co-administration timing

### V. Definitions

- define singular forms
- interpret range of values
- define recombinant
- describe recombinant techniques
- define subject, individual, or patient
- define associated
- describe physiological conditions
- define pharmaceutically acceptable excipient or carrier
- define excipient or vehicle
- define permeant, drug, or pharmacologically active agent
- describe about
- define optional or optionally
- define substantially absent or substantially free
- define pharmacologically effective amount or therapeutically effective amount
- describe biological activity
- define nucleic acid
- define variant
- define mutant
- define native or wild-type

### VI. Examples

- introduce experimental procedures
- describe chemicals used
- describe animal procedures
- determine metabolite concentrations
- perform size exclusion chromatography-HPLC
- perform non-reduced capillary electrophoresis
- perform protein gel electrophoresis
- perform CBS activity assays
- perform PEGylation mapping
- perform statistical analysis
- optimize PEGylation of htCBS C15S
- separate PEG-htCBS C15S species
- identify sites of maleimide PEGylation
- analyze PEGylation patterns
- reproduce PEGylation of htCBS C15S with NHS ester PEG molecules
- analyze impact of NHS ester PEG molecules on enzyme activity
- separate NHS PEG-htCBS C15S conjugates
- characterize extent of PEGylation using NHS ester PEG molecules
- identify lysine residues involved in PEGylation
- perform LC-MS analysis
- estimate PEGylation extent
- identify PEGylated peptides
- perform LC-MS analysis (batch #2)
- estimate PEGylation extent (batch #2)
- identify PEGylated peptides (batch #2)
- perform LC-MS analysis (batch #3)
- estimate PEGylation extent (batch #3)
- identify PEGylated peptides (batch #3)
- describe attenuation of PEG-htCBS C15S efficacy
- describe approach to reduce attenuation
- describe dosing regimen
- describe retaining efficacy of 20NHS PEG-htCBS
- describe rescuing phenotype of KO mice
- introduce examples
- describe body weight and weight gain of mice
- compare body weight and weight gain between groups
- describe sustained efficacy of 20NHS PEG-htCBS C15S
- show plasma metabolite levels over time
- describe normalization of tissue metabolite levels
- compare metabolite levels between groups
- describe methylation capacity in mice
- compare methylation capacity between groups
- describe pharmacokinetics of 20NHS PEG-htCBS C15S in rats
- show plasma activity of 20NHS PEG-htCBS C15S over time
- describe repeated dosing study in rats
- compare plasma levels between sexes and doses
- discuss predicted steady state plasma levels

## EQUIVALENTS AND SCOPE

- define scope of invention
- interpret claim language
- disclaim limitations

